CFZ533   

GtoPdb Ligand ID: 9802

Synonyms: CFZ-533 | iscalimab (proposed INN) | NVP-CFZ533 | OM11-62MF
Compound class: Antibody
Comment: CFZ533 is an anti-CD40 monoclonal antibody that is designed exhibit no agonist activity and is non-depleting (no ADCC activity for an improved safety profile, particularly in non-oncologic indications). It is claimed in Novartis' patent WO2012065950 [1] as mAb1 (based on peptide sequence alignments between the INN record for iscalimab and patented sequences retrieved from a BLAST search). Blocking CD40-mediated inflammatory responses is a well advanced mechanism being expoited for potential to treat autoimmune and inflammatory disorders and/or for preventing/reducing graft rejection following organ transplant.
Immunopharmacology Comments
CFZ533 is an anti-CD40 mAb that is being evaluated in clinical trials as a therapy for some autoimmune conditions and for preventing/reducing solid organ transplant rejection. It blocks CD40-CD40L signalling capacity [1].
Immunopharmacology Disease
Disease X-Refs Comment References
Graves' disease Disease Ontology: DOID:12361
Phase 2 clinical candidate for Graves' disease- see NCT02713256
Myasthenia gravis Disease Ontology: DOID:437
OMIM: 254200
Orphanet: ORPHA589
Phase 2 clinical candidate for moderate to severe Myasthenia gravis- see NCT02565576
Sjögren's syndrome Orphanet: ORPHA378
Phase 2 clinical candidate for primary Sjögren's syndrome- see NCT02291029
Rheumatoid arthritis Disease Ontology: DOID:7148
OMIM: 180300
Phase 1 clinical candidate for RA- see completed trial NCT02089087